Cargando…

The Clinical and Epidemiological Profile of Paediatric-Onset Multiple Sclerosis in Poland

Background. Paediatric-onset MS (POMS) has a unique clinical profile compared to the more prevalent adult-onset MS. For this study, we aimed to determine the demographic and clinical characteristics of POMS in Poland as well as addressing some of its epidemiological aspects. Methods. A retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Brola, Waldemar, Steinborn, Barbara, Żak, Marek, Mazurkiewicz-Bełdzińska, Maria, Jóźwiak, Sergiusz, Sobolewski, Piotr, Wilski, Maciej, Bilska, Małgorzata, Siedlarska, Magdalena, Puzio-Bochen, Iwona, Wencel-Warot, Agnieszka, Lemka, Małgorzata, Kroczka, Sławomir, Czyżyk, Elżbieta, Bocheńska, Małgorzata, Emich-Widera, Ewa, Pietruszewski, Jerzy, Boćkowski, Leszek, Kapica-Topczewska, Katarzyna, Czarnowska, Agata, Kułakowska, Alina, Ujma-Czapska, Barbara, Gruna-Ożarowska, Agata, Przysło, Łukasz, Połatyńska, Katarzyna, Dudzińska, Magdalena, Mitosek-Szewczyk, Krystyna, Melnyk, Aleksandra, Adamczyk-Sowa, Monika, Kotulska, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785459/
https://www.ncbi.nlm.nih.gov/pubmed/36556109
http://dx.doi.org/10.3390/jcm11247494
Descripción
Sumario:Background. Paediatric-onset MS (POMS) has a unique clinical profile compared to the more prevalent adult-onset MS. For this study, we aimed to determine the demographic and clinical characteristics of POMS in Poland as well as addressing some of its epidemiological aspects. Methods. A retrospective study was conducted based on the Polish Multiple Sclerosis Registry, considering a population of children and adolescents with MS (age ≤ 18 years). Data were collected by all 13 centres across Poland specializing in diagnosing and treating POMS. The actual course of the disease and its clinical properties were compared between child (≤12 years) and juvenile (>12 years) patients. MS onset and its prevalence were assessed at the end of 2019, stratified by age range. Results. A total of 329 paediatric or juvenile patients (228 girls, 101 boys) with a clinically definite diagnosis of MS, in conformity with the 2017 McDonald Criteria, were enrolled. For 71 children (21.6%), the first symptoms appeared before the age of 12. The female: male ratio increased with age, amounting to 1:1 in the ≤12 years group and to 2.9:1 in the >12 years group. In most cases, the disease had multi-symptomatic onset (31.3%), and its course was mostly of a relapsing–remitting character (95.7%). The initial Expanded Disability Status Score for both groups was 1.63 ± 1.1, whereas the annual relapse rate was 0.84 during the first 2 years. The time between the onset of symptoms and diagnosis was longer in the younger patients (8.2 ± 4.2 vs. 4.6 ± 3.6 months; p < 0.005). On 31 December 2019, the age-adjusted prevalence standardized to the European standard population was 5.19/100,000 (95% CI, 4.64–5.78). Significantly higher prevalence was noted in the 13–18 years group (7.12; 95% CI, 6.64–7.86) than in the 9–12 years group (3.41; 95% CI, 2.98–3.86) and the <9 years group (0.56; 95% CI, 0.46–0.64; p < 0.001). Conclusion. POMS commencing at the age of ≤12 years is rare, differing significantly from the juvenile-onset and adult MS in terms of clinical characteristics, course, and incidence, as stratified by gender.